Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION In a safety team sitting on a new disproportionate signal, inspection-readiness findings at a CMO is the evidence after a site-change that invalidates stability claims. 505(b)(2) development lead has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Pharmacovigilance close using inspection-readiness findings at a CMO.

DECISION 505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. 505(b)(2) development lead can defend Proceed under protocol from inspection-readiness findings at a CMO after a site-change that invalidates stability claims in a Pharma & Life Sciences challenge. 2. 505(b)(2) development lead cannot defend Proceed under protocol from inspection-readiness findings at a CMO; Pause the pathway is what the extract actually supports after a site-change that invalidates stability claims. 3. A site-change that invalidates stability claims never reached the population in inspection-readiness findings at a CMO — reopen intake, do not close the 505(b)(2) bridge is. 4. Two facts in inspection-readiness findings at a CMO after a site-change that invalidates stability claims conflict for 505(b)(2) development lead; hold this Pharmacovigilance file.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 2. Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after a site-change that invalidates stability claims. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Pharmacovigilance file, read inspection-readiness findings at a CMO against a site-change that invalidates stability claims and write the one fact that would move the 505(b)(2) bridge is for 505(b)(2) development lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (inspection-readiness findings at a CMO after a site-change that invalidates stability claims). The follow-on Pharmacovigilance action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the 505(b)(2) bridge is, then the evidence in inspection-readiness findings at a CMO, then the action for 505(b)(2) development lead - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - Pharmacovigilance finding in inspection-readiness findings at a CMO that a second reviewer can re-perform - Missing page in inspection-readiness findings at a CMO after a site-change that invalidates stability claims, if any